

> E HANGELAND JON/AU 25

E1	1	HANGELAND ERIK/AU
E2	2	HANGELAND J J/AU
E3	2 -->	HANGELAND JON/AU
E4	9	HANGELAND JON J/AU
E5	1	HANGELAND JON JOSEF/AU
E6	1	HANGELBROEK H H/AU
E7	2	HANGELBROEK R J/AU
E8	1	HANGEN DIETHER/AU
E9	3	HANGEN DONALD H/AU
E10	1	HANGEN E/AU
E11	4	HANGEN HERMANN OTTO/AU
E12	1	HANGEN L/AU
E13	1	HANGEN M/AU
E14	2	HANGEN MATTHIAS/AU
E15	1	HANGEN NINA/AU
E16	1	HANGEN THAD C/AU
E17	9	HANGEN U/AU
E18	2	HANGEN U D/AU
E19	6	HANGEN UDE/AU
E20	4	HANGEN UDE D/AU
E21	1	HANGENFELDT KERSTIN A/AU
E22	1	HANGER B/AU
E23	17	HANGER B C/AU
E24	1	HANGER C/AU
E25	3	HANGER CHRISTOPHER C/AU

=> S (E2 OR E3 OR E4 OR E5) AND (?THYROID?)

2 "HANGELAND J J"/AU
2 "HANGELAND JON"/AU
9 "HANGELAND JON J"/AU
1 "HANGELAND JON JOSEF"/AU

96884 ?THYROID?

L1 1 ("HANGELAND J J"/AU OR "HANGELAND JON"/AU OR "HANGELAND JON J"/AU OR "HANGELAND JON JOSEF"/AU) AND (?THYROID?)

=> DIS L1 1 IBIB ABS

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:457018 CAPLUS

DOCUMENT NUMBER: 133:89793

TITLE: Preparation of 4-(4-hydroxyphenoxy)phenylacetyl amino acids and related compounds as novel **thyroid** receptor ligands

INVENTOR(S): **Hangeland, Jon**; Zhang, Minsheng; Caringal, Yolanda; Ryono, Denis; Li, Yi-lin; Malm, Johan; Liu, Ye; Garg, Neeraj; Litten, Chris; Garcia Collazo, Ana Maria; Koehler, Konrad

PATENT ASSIGNEE(S): Karo Bio AB, Swed.; et al.

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2000039077	A2	20000706	WO 1999-IB2084	19991223
WO 2000039077	A3	20000921		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,

IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2356319 AA 20000706 CA 1999-2356319 19991223
BR 9916851 A 20011016 BR 1999-16851 19991223
EP 1144370 A2 20011017 EP 1999-962486 19991223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2002533432 T2 20021008 JP 2000-590990 19991223
NO 2001002931 A 20010821 NO 2001-2931 20010613
PRIORITY APPLN. INFO.: GB 1998-28442 A 19981224
WO 1999-IB2084 W 19991223
OTHER SOURCE(S): MARPAT 133:89793
GI



AB Title compds. I [R1 = halo, trifluoromethyl, alkyl, cycloalkyl; R2, R3 = H, halo, alkyl, at least one of R2 and R3 being other than H; n = 0-4; R4 is an (un)substituted heteroarom. moiety linked to (CH2)n via a nitrogen or carbon atom; an amine, including those in which the amine is derived from an alpha amino acid of either L- or D-stereochem., an acylsulfonamide, or a carboxylic acid amide, with the proviso that when n = 0, then R4 can only be a carboxylic acid amide or an acylsulfonamide; R5 is H or an acyl or other group capable of bioconversion to generate the free phenol structure] were prepd. for use in the treatment of diseases assocd. with metab. dysfunction or which are dependent on the expression of a T3 regulated gene (such as obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, **hypothyroidism**, goiter, **thyroid** cancer, glaucoma, cardiac arrhythmia, and congestive heart failure). Thus, coupling of 3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetic acid with D-methionine Me ester hydrochloride followed by hydrolysis afforded N-[3,5-dibromo-4-(4-hydroxy-3-isopropylphenoxy)phenylacetyl]-D-methionine.